Telix Pharmaceuticals Ltd — Capital/Financing Update 2022

Mar 1, 2022

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [146 x 81] intentionally omitted <==

ASX RELEASE

Cancellation of Share Purchase Plan

Melbourne (Australia) – 2 March 2022 . Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company is immediately cancelling the Share Purchase Plan (SPP) announced on 24 January 2022.

The cancellation of the SPP does not affect the recently completed share placement to institutional investors which raised $175 million at $7.70 per share (Placement).[1]

The SPP was undertaken in order to enable eligible shareholders to subscribe for new shares at the same price as the shares issued under the Placement. The decision to cancel the SPP was made by the Board after considering current market conditions, which have changed significantly in recent weeks.

Telix has no current intention to undertake a new share purchase plan.

Any application monies already received under the SPP offer will be refunded in full, without interest, per the terms set out in the SPP booklet and no new shares will be issued under the SPP.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s lead product, gallium-68 ([68] Ga) gozetotide (also known as[68] Ga PSMA-11) injection for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),[2] and by the Australian Therapeutic Goods Administration (TGA).[3] Telix is also progressing marketing authorisation applications for this investigational candidate in Europe[4] and Canada.[5]

Telix Investor Relations

Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer.

1 ASX disclosure 24 January 2022.

2 ASX disclosure 20 December 2021.

3 ASX disclosure 2 November 2021.

4 ASX disclosure 10 December 2021.

5 ASX disclosure 16 December 2020.

Page 1 tepl0001_2100049_034.docx

Legal Notices

This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and”guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forwardlooking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forwardlooking statements.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.

The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

Page 2 tepl0001_2100049_034.docx